Highlights
- ALS (ASX:ALQ) opened a new geochemistry hub laboratory in Lima, Peru, in October 2026.
- The Lima Facility represents approximately AUD 70 million of Investment and capacity above four million samples annually.
- FY26 Revenue rose 10.7% to AUD 3.32 billion, while underlying EBIT increased 19.3% to AUD 599.0 million.
- The company has scheduled publication of its H1 FY27 results for November 23, 2026.
ALS Limited supplies laboratory testing, inspection and analytical services to mining, environmental, food and pharmaceutical customers worldwide. On November 19, 2026, shares in ALS (ASX:ALQ) traded at AUD 20.26, down 1.46% during the session. Its latest operational developments include the opening of a major geochemistry laboratory in Peru ahead of its scheduled half-year results.
New Lima Geochemistry Laboratory Expands Testing Capacity
In late October 2026, ALS announced the opening of a geochemistry hub laboratory in Lima, Peru. The facility represents an investment of approximately AUD 70 million and occupies about 9,000 square metres of laboratory and operating space. The company stated that the site can process more than four million samples annually, using analytical instruments, automation, sample preparation and Warehousing facilities.
Minerals Testing, Environmental Services and Food Laboratories
ALS reports through two main operating divisions, Commodities and Life Sciences. Commodities provides geochemistry, metallurgical and other analytical services across mineral exploration, Mining and related markets. Life Sciences encompasses environmental, food and pharmaceutical testing. The mix provides exposure to differing customer budgets and regulatory requirements, although changes in activity can affect individual services unevenly.
FY26 Revenue, Earnings and Cash Flow
For the year ended March 31, 2026, ALS reported revenue of AUD 3,320.1 million, compared with AUD 2,999.4 million in FY25, an increase of 10.7%. Underlying earnings before interest and tax rose 19.3% to AUD 599.0 million, while the underlying EBIT Margin increased to 18.0% from 16.7%. The company reported statutory net profit after tax of AUD 318.7 million, up 24.4%.
Underlying net profit after tax reached AUD 381.2 million, rising 25.8%, while reported free Cash Flow generated increased 14.1% to AUD 674.1 million. Net Debt was AUD 1,069.5 million at March 31, 2026, versus AUD 1,424.1 million a year earlier. Underlying measures exclude specified items and should be distinguished from statutory earnings.
Commodities revenue increased 18.8% to AUD 1,294.2 million, with underlying EBIT rising 25.9% to AUD 381.5 million. ALS attributed activity to greater mineral exploration sample volumes and improving pricing. Life Sciences revenue rose 6.0% to AUD 2,025.9 million and underlying EBIT rose 10.2% to AUD 296.5 million. Food contributed to divisional growth, while environmental and pharmaceutical businesses produced mixed outcomes.
Capital Projects, Integration and Operational Risks
ALS’s FY26 reporting described a laboratory expansion programme covering Lima as well as environmental laboratory hubs in Sydney, Bangkok and Prague. New capacity requires spending before utilisation is fully established, making laboratory commissioning, sample volumes, operating efficiency and customer retention relevant monitoring points. Mining-related laboratory Demand is exposed to changes in exploration expenditure and Commodity industry activity.
November Half-Year Reporting and What to Watch
ALS has scheduled its H1 FY27 results announcement and Interim Dividend declaration for November 23, 2026, covering the half-year ended September 30. That release will provide the next company-wide financial update after the FY26 results. Key disclosures to monitor include Commodities testing volumes and pricing, Life Sciences demand, laboratory margins, cash generation and the financial impact of recent investments.
Key Insights
ALS enters its forthcoming half-year reporting period after opening a major geochemistry facility in Peru and expanding testing services in India. FY26 results showed higher group revenue, earnings and free cash flow, with faster growth in Commodities than Life Sciences. The next report will clarify whether Volume trends, laboratory utilisation and divisional margins have changed during H1 FY27.






Please wait processing your request...